Identification of immunodominant ERV peptides critical for anti-metastatic immunity in a model of TNBC
The integration of immunotherapy into neoadjuvant treatment for triple-negative breast cancer (TNBC) has improved outcomes in some patients. Pre-clinical investigation of immunotherapy resistance in the aggressive 4T1 TNBC model has been hampered by a lack of known tumour-specific epitopes. Using proteomic and functi...